Effects of Rituximab on JAK-STAT and NF-kappa B signaling pathways in acute lymphoblastic leukemia and chronic lymphocytic leukemia
Articles > Article · 2019
Authors: Aysegul Dalmlzrak, Nur SELVİ GÜNEL, Burçin KAYMAZ, Fahri ŞAHİN, Güray SAYDAM, Buket KOSOVA
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, Journal Indexed in SCI Expanded, International, 2019, vol 44, pp 499-509
Summary
Objectives: Rituximab is a monoclonal antibody that targets the B-lymphocyte surface antigen CD20. It is used in the treatment of some diseases including B-cell chronic lymphocytic leukemia (B-CLL). There are a lot of data regarding effect of Rituximab on lymphoma cells. But, there is no satisfactory information about the effect of Rituximab on the signaling pathways in leukemia cells. In this study, it was aimed to understand the effect of Rituximab on JAK-STAT and NF-kappa B signaling pathways in B-cell acute lymphoblastic leukemia (B-ALL) and B-CLL.